Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 4/20 | 0.51 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18921612 | 0.90 | NR1H2 (0.55) | NR1H2NR1H3CNR1GPR119 | |
| SCHEMBL18921618 | 0.87 | NR1H2 (0.59) | NR1H2NR1H3GPR119MAPT | |
| SCHEMBL3486236 | 0.86 | NR1H2 (0.66) | NR1H2NR1H3GPR119 | |
| SCHEMBL18921589 | 0.85 | NR1H2 (0.54) | NR1H2NR1H3GPR119MAPT | |
| SCHEMBL18921637 | 0.85 | GPR119 (0.58) | NR1H2NR1H3GPR119 | |
| SCHEMBL18921600 | 0.84 | NR1H2 (0.51) | NR1H2NR1H3CNR1GPR119 | |
| SCHEMBL22625866 | 0.84 | NR1H2 (0.53) | NR1H2NR1H3DRD2MAPT | |
| SCHEMBL18921605 | 0.81 | NR1H2 (0.48) | NR1H2NR1H3DRD2 | |
| SCHEMBL30032623 | 0.81 | NR1H2 (0.49) | NR1H2NR1H3GPR119MAPT | |
| SCHEMBL30906299 | 0.80 | GPR119 (0.47) | CNR1GPR119TGFBR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3383853-B1 | HOMOBISPIPERIDINYL DERIVATIVES AS LIVER X RECEPTOR (LXR) BETA AGONISTS FOR TREATING E.G. ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (US) | 2020-11-04 | — | — | EP | disclosed |
| US-10752587-B2 | Homobispiperidinyl derivatives as liver X receptor beta agonists, compositions and their use | MERCK SHARP & DOHME CORP. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20180354901-A1 | HOMOBISPIPERIDINYL DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2018-12-13 | — | — | US | disclosed |
| WO-2017095758-A1 | HOMOBISPIPERIDINYL DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2017-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10752587-B2 | Homobispiperidinyl derivatives as liver X receptor beta agonists, compositions and their use | NR1H2, NR1H3, NR1H4 | NR1H2 1/4885NR1H3 2/4885CNR1 94/4885 |
| US-20180354901-A1 | HOMOBISPIPERIDINYL DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS AND THEIR USE | NR1H2, NR1H3, NR1H4 | NR1H2 1/4885NR1H3 2/4885CNR1 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.